



## **Othera Pharmaceuticals Appoints Al Reaves as Senior Vice President of Clinical Development**

**Exton, PA, March 22, 2006 – Othera Pharmaceuticals Inc.**, a privately-held specialty pharmaceutical company developing proprietary drugs to treat or prevent the three leading causes of blindness, announced today that it has appointed Al Reaves, Ph.D., as Senior Vice President of Clinical Development.

Dr. Al Reaves has 22 consecutive years of ophthalmology drug development experience. During his career, he has been responsible for bringing numerous ophthalmic products to market, and previously, led the Visudyne global clinical development program at Novartis and worked with the Genentech/Novartis partnership for Lucentis approval in Europe. Throughout his career he has served as the Head of Clinical and Regulatory Affairs at Xenon Vision, as well as the Manager of Clinical Research at Alcon Laboratories.

“Dr. Reaves brings to Othera extensive experience in clinical development, including the firsthand knowledge required to take ophthalmology products from initial discovery to successful regulatory submission,” said David S. Joseph, Chairman and CEO of Othera. “With two lead compounds in clinical development, and six clinical trials either underway or planned over the next 12 months, Othera is well-positioned to develop first-in-class treatments for the leading causes of blindness, including dry and wet AMD, cataracts and glaucoma.”

“Othera’s robust pipeline of ophthalmic products for major indications was a major attraction for me,” said Reaves. “I look forward to working closely with the management team at Othera to bring these topically dosed ophthalmic treatments to market.”

Dr. Reaves has published more than 80 articles in scientific publications. He received his Ph.D. in Neuroscience from the University of Illinois.

### **About Othera Pharmaceuticals**

Founded in 2002, Othera Pharmaceuticals, Inc. is a specialty pharmaceuticals company focused on developing treatments for the leading causes of blindness and vision impairment. Othera’s lead compound, OT-551, an eye drop, is being developed to treat several major eye diseases and conditions, including the dry and wet forms of age-related macular degeneration (AMD), cataracts and dry eye syndrome. Othera is also developing OT-730, a novel improved beta-blocker for treatment of glaucoma. For more information please visit Othera's website at [www.othera.com](http://www.othera.com).

###

### **Contact:**

Matt Dallas  
Financial Dynamics  
212-850-5627  
mdallas@fd.com